Nektar Therapeutics (NKTR) EBIAT (2016 - 2025)
Historic EBIAT for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.5 million.
- Nektar Therapeutics' EBIAT rose 414.23% to -$35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.7 million, marking a year-over-year increase of 2826.19%. This contributed to the annual value of -$119.0 million for FY2024, which is 5690.69% up from last year.
- Per Nektar Therapeutics' latest filing, its EBIAT stood at -$35.5 million for Q3 2025, which was up 414.23% from -$41.6 million recorded in Q2 2025.
- Nektar Therapeutics' 5-year EBIAT high stood at $7.3 million for Q4 2024, and its period low was -$159.1 million during Q2 2022.
- Its 5-year average for EBIAT is -$74.5 million, with a median of -$52.4 million in 2024.
- Per our database at Business Quant, Nektar Therapeutics' EBIAT tumbled by 5689.88% in 2021 and then surged by 11725.56% in 2024.
- Nektar Therapeutics' EBIAT (Quarter) stood at -$145.6 million in 2021, then soared by 59.02% to -$59.7 million in 2022, then rose by 29.5% to -$42.1 million in 2023, then surged by 117.26% to $7.3 million in 2024, then tumbled by 589.22% to -$35.5 million in 2025.
- Its EBIAT stands at -$35.5 million for Q3 2025, versus -$41.6 million for Q2 2025 and -$50.9 million for Q1 2025.